forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide RA prescription trends: January 2018 – March forecast glp-1 prescriptions growth 2025

Spending on shareholder enrichment appears to take priority over research and development (R&D), with Novo Nordisk spending 41% more on dividends and buybacks than on R&D over the past five years

Anyone evaluating a tirzepatide telehealth platform in 2026 - including MEDVi - should seek out the most current information about that platform's regulatory compliance, medication sourcing, and pharmacy partnerships before proceeding

Total antioxidant status and total oxidant status in the brain of H

More people are becoming overweight, leading to serious health issues like heart disease, diabetes, and high blood pressure